Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
Verify pharmacy licensing, quality standards, and prescriber credentials separately
We acknowledge that this was a small study, so statistical variability could allow for the true effect to be smaller than what we observed
For instance, one trial modeled AOD 9604 with and without hyaluronic acid (HA) in a collagenase-induced osteoarthritis model
As fat levels drop, metabolism slows down to save energy
Callaghan and his colleagues followed 46 patients with diabetes who took exenatide (Byetta), another GLP-1 receptor agonist, for 18 months and found that those patients didn't control their blood glucose levels or symptoms of diabetic neuropathy better than patients who took insulin
